# EDGAR Filing Document

**Accession Number:** 0001022079
**File Stem:** 0001022079-26-000040
**Filing Date:** 2026-4
**Character Count:** 30107
**Document Hash:** 033ef17960b584ba0d47397855ae7e2e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001022079-26-000040.hdr.sgml**: 20260421

**ACCESSION NUMBER**: 0001022079-26-000040

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260421

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260421

**DATE AS OF CHANGE**: 20260421

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** QUEST DIAGNOSTICS INC
- **CENTRAL INDEX KEY:** 0001022079
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 161387862
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-12215
- **FILM NUMBER:** 26876690

**BUSINESS ADDRESS:**
- **STREET 1:** 500 PLAZA DRIVE
- **CITY:** SECAUCUS
- **STATE:** NJ
- **ZIP:** 07094
- **BUSINESS PHONE:** 9735202700

**MAIL ADDRESS:**
- **STREET 1:** 500 PLAZA DRIVE
- **CITY:** SECAUCUS
- **STATE:** NJ
- **ZIP:** 07094

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CORNING CLINICAL LABORATORIES INC
- **DATE OF NAME CHANGE:** 19960903

?xml version='1.0' encoding='ASCII'? dgx-20260421

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

**FORM 8-K** 

**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report** (Date of Earliest Event Reported)**: April 21, 2026** 

**Quest Diagnostics Incorporated**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware** 

(State or other jurisdiction of incorporation)

---

| | | | | |
|:---|:---|:---|:---|:---|
| **001-12215** | **001-12215** | | | **16-1387862** |
| (Commission File Number) | (Commission File Number) |  |  | (I.R.S. Employer Identification No.) |
| **500 Plaza Drive** | **500 Plaza Drive** |  |  |  |
| **Secaucus,** | **NJ** |  |  | **07094** |
| (Address of principal executive offices) | (Address of principal executive offices) |  |  | (Zip Code) |
|  |  | **(973)** | **520-2700** |  |
| (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u> General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.01 Par Value | DGX | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

&nbsp;&nbsp;&nbsp;&nbsp;Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02. Results of Operations and Financial Condition**

On April 21, 2026, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

&nbsp;&nbsp;&nbsp;&nbsp;

**Item 9.01. Financial Statements and Exhibits**

---

| | | |
|:---|:---|:---|
| d. | <u>Exhibit</u> | |
| | 99.1 | <u>[Press release of Quest Diagnostics Incorporated dated April 21, 2026, announcing, among other things, its results for the quarter ended March 31, 2026.](dgx033120268-kex991.htm)</u> |
| | 104 | The cover page from this current report on Form 8-K, formatted in Inline XBRL. |

---

------

**Signature**

&nbsp;&nbsp;&nbsp;&nbsp;

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

April 21, 2026

---

| | |
|:---|:---|
| QUEST DIAGNOSTICS INCORPORATED | QUEST DIAGNOSTICS INCORPORATED |
| By: | /s/ Sean D. Mersten |
|  | Sean D. Mersten |
|  | Vice President and Corporate Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**

**Quest Diagnostics Reports First Quarter 2026 Financial Results;** 

**Raises Revenue and EPS Guidance for Full Year 2026**

&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growth

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• First quarter reported diluted earnings per share ("EPS") of $2.24, up 15.5% from 2025; and adjusted diluted EPS of $2.50, up 13.1% from 2025

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Full year 2026 reported diluted EPS now expected to be between $9.58 and $9.78; and adjusted diluted EPS is expected to be between $10.63 and $10.83

SECAUCUS, N.J., April 21, 2026 - Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2026.

"Our more than 9% revenue growth, almost entirely organic, and approximately 13% adjusted diluted earnings per share growth reflect our team's disciplined execution of our strategy to deliver innovative diagnostic solutions for our customers' evolving needs," said Jim Davis, Chairman, CEO and President. "We are raising our revenue and EPS guidance for the year, given our robust first quarter performance and continued strategic focus."

**Recent Highlights:**

<u>Serving Clinicians and Health Systems</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Continued to advance our Co-Lab Solutions implementation and joint venture laboratory with Corewell Health, a leading health system in Michigan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Scaled our lab and water purity testing solutions for several dialysis clinics and hospitals, extending our reach beyond dialysis clinics owned by Fresenius Medical Care in the United States.

<u>Serving Consumers</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Grew revenues robustly across the consumer channel through our questhealth.com platform and collaborations with top consumer health companies.

<u>Delivering Diagnostic Innovations</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Generated double-digit revenue growth in several areas of Advanced Diagnostics, including for our Quest AD-Detect® blood tests for Alzheimer's disease and in several clinical areas of advanced cardiometabolic and endocrine disease.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Formed a research collaboration with City of Hope to study the use of Haystack MRD® as an aid in cancer monitoring and treatment decisions for four solid tumor cancers at 14 U.S. sites.

<u>Driving Operational Excellence</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Launched our AI Companion tool to help patients better understand their lab test reports. Patients have engaged Quest AI Companion approximately 350,000 times since we rolled it out to users of our myQuest patient app earlier this quarter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Advanced our planning and design work for Project Nova, our multi-year initiative to transform our order-to-cash processes and systems, with plans to implement our first wave of solutions in the fall of 2027.

------

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** | **Change** |
| | (dollars in millions, except per share data) | (dollars in millions, except per share data) | (dollars in millions, except per share data) |
| **<u>Reported:</u>** |  |  |  |
| Net revenues | $2895 | $2652 | 9.2% |
| &nbsp;&nbsp;Diagnostic Information Services revenues | $2832 | $2589 | 9.4% |
| &nbsp;&nbsp;&nbsp;Revenue per requisition |  |  | (1.3)% |
| &nbsp;&nbsp;&nbsp;Requisition volume |  |  | 10.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;Organic requisition volume |  |  | 10.8% |
| Operating income (a) | $399 | $346 | 15.5% |
| Operating income as a percentage of net revenues (a) | 13.8% | 13.0% | 0.8% |
| Net income attributable to Quest Diagnostics (a) | $252 | $220 | 14.4% |
| Diluted EPS (a) | $2.24 | $1.94 | 15.5% |
| Cash provided by operations | $278 | $314 | (11.6)% |
| Capital expenditures | $114 | $117 | (1.8)% |
| **<u>Adjusted (a):</u>** |  |  |  |
| Operating income | $447 | $406 | 10.0% |
| Operating income as a percentage of net revenues | 15.4% | 15.3% | 0.1% |
| Net income attributable to Quest Diagnostics | $281 | $251 | 12.1% |
| Diluted EPS | $2.50 | $2.21 | 13.1% |

---

(a)For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below.

**Updated Guidance for Full Year 2026**

The company updates its full year 2026 guidance as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Updated Guidance** | **Updated Guidance** | **Prior Guidance** | **Prior Guidance** |
| | **Low** | **High** | **Low** | **High** |
| Net revenues | $11.78 billion | $11.90 billion | $11.70 billion | $11.82 billion |
| &nbsp;&nbsp;Net revenues increase | 6.8% | 7.8% | 6.0% | 7.1% |
| Reported diluted EPS | $9.58 | $9.78 | $9.45 | $9.65 |
| Adjusted diluted EPS | $10.63 | $10.83 | $10.50 | $10.70 |
| Cash provided by operations | Approximately $1.75 billion | Approximately $1.75 billion | Approximately $1.75 billion | Approximately $1.75 billion |
| Capital expenditures | &nbsp;&nbsp;&nbsp;&nbsp;Approximately $550 million | &nbsp;&nbsp;&nbsp;&nbsp;Approximately $550 million | Approximately $550 million | Approximately $550 million |

---

**Note on Non-GAAP Financial Measures**

As used in this press release the term "reported" refers to measures under accounting principles generally accepted in the United States ("GAAP"). The term "adjusted" refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, gains and losses associated with changes in the carrying value of our strategic investments and other items.

Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures.

------

**Conference Call Information** 

Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: 7895081; or via live webcast on our website at www.QuestDiagnostics.com/investor. We suggest participants dial in approximately 10 minutes before the call.

A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or, from approximately 10:30 a.m. Eastern Time on April 21, 2026 until midnight Eastern Time on May 5, 2026, by phone at 866-388-5361 for domestic callers or 203-369-0416 for international callers. Anyone listening to the call is encouraged to read our periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

**About Quest Diagnostics**

Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We help connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, our insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three adult Americans each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com.

**Forward Looking Statements**

The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, uncertain and volatile economic conditions, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government policies, including related to trade, and regulations, changing relationships with customers, payers, suppliers or strategic partners, acquisitions and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.

For further information: Wendy Bost, Quest Diagnostics (Media): 973-520-2800, Daniel Haemmerle, Quest Diagnostics (Investors): 973-520-2900

This earnings release, including the attached financial tables, is available online in the Newsroom section at www.QuestDiagnostics.com.

ADDITIONAL TABLES FOLLOW

------

**Quest Diagnostics Incorporated and Subsidiaries**

**Consolidated Statements of Operations**

**For the Three Months Ended March 31, 2026 and 2025** 

**(in millions, except per share data)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **Net revenues** | $2895 | $2652 |
| **Operating costs and expenses and other operating income:** |  |  |
| Cost of services | 1953 | 1789 |
| Selling, general and administrative | 504 | 476 |
| Amortization of intangible assets | 37 | 39 |
| Other operating expense, net | 2 | 2 |
| &nbsp;&nbsp;&nbsp;Total operating costs and expenses, net | 2496 | 2306 |
| **Operating income** | 399 | 346 |
| **Other income (expense):** |  |  |
| Interest expense, net | (63) | (67) |
| Other expense, net | (2) | (3) |
| &nbsp;&nbsp;&nbsp;Total non-operating expense, net | (65) | (70) |
| **Income before income taxes and equity in earnings of equity method investees** | 334 | 276 |
| **Income tax expense** | (74) | (59) |
| **Equity in earnings of equity method investees, net of taxes** | 4 | 18 |
| **Net income** | 264 | 235 |
| **Less: Net income attributable to noncontrolling interests** | 12 | 15 |
| **Net income attributable to Quest Diagnostics** | $252 | $220 |
| **Earnings per share attributable to Quest Diagnostics' common stockholders:** |  |  |
| Basic | $2.27 | $1.97 |
| Diluted | $2.24 | $1.94 |
| **Weighted average common shares outstanding:** |  |  |
| Basic | 110 | 111 |
| Diluted | 112 | 113 |

---

------

**Quest Diagnostics Incorporated and Subsidiaries**

**Consolidated Balance Sheets**

**March 31, 2026 and December 31, 2025** 

**(in millions, except per share data)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| **<u>Assets</u>** | | |
| **Current assets:** | | |
| Cash and cash equivalents | $393 | $420 |
| Accounts receivable, net | 1587 | 1408 |
| Inventories | 225 | 189 |
| Prepaid expenses and other current assets | 361 | 361 |
| &nbsp;&nbsp;&nbsp;Total current assets | 2566 | 2378 |
| **Property, plant and equipment, net** | 2189 | 2203 |
| **Operating lease right-of-use assets** | 691 | 657 |
| **Goodwill** | 9120 | 8945 |
| **Intangible assets, net** | 1717 | 1636 |
| **Investments in equity method investees** | 134 | 136 |
| **Other assets** | 256 | 270 |
| **Total assets** | $16673 | $16225 |
| **<u>Liabilities and Stockholders' Equity</u>** |  |  |
| **Current liabilities:** |  |  |
| Accounts payable and accrued expenses | $1500 | $1600 |
| Current portion of long-term debt | 503 | 504 |
| Current portion of long-term operating lease liabilities | 174 | 174 |
| &nbsp;&nbsp;&nbsp;Total current liabilities | 2177 | 2278 |
| **Long-term debt** | 5155 | 5167 |
| **Long-term operating lease liabilities** | 574 | 537 |
| **Other liabilities** | 1022 | 957 |
| **Redeemable noncontrolling interest** | 79 | 80 |
| **Stockholders' equity:** |  |  |
| Quest Diagnostics stockholders' equity: |  |  |
| &nbsp;&nbsp;Common stock, par value $0.01 per share; 600 shares authorized as of both March 31, 2026 and December 31, 2025; 162 shares issued as of both March 31, 2026 and December 31, 2025 | 2 | 2 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 2347 | 2381 |
| &nbsp;&nbsp;&nbsp;Retained earnings | 10151 | 9994 |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (43) | (27) |
| &nbsp;&nbsp;Treasury stock, at cost; 51 shares and 52 shares as of March 31, 2026 and December 31, 2025, respectively | (5091) | (5180) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Quest Diagnostics stockholders' equity | 7366 | 7170 |
| &nbsp;&nbsp;&nbsp;Noncontrolling interests | 300 | 36 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 7666 | 7206 |
| **Total liabilities and stockholders' equity** | $16673 | $16225 |

---

------

**Quest Diagnostics Incorporated and Subsidiaries**

**Consolidated Statements of Cash Flows**

**For the Three Months Ended March 31, 2026 and 2025** 

**(in millions)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **Cash flows from operating activities:** |  |  |
| Net income | $264 | $235 |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| Depreciation and amortization | 147 | 140 |
| Provision for credit losses | 1 | 1 |
| Deferred income tax expense | 48 | 7 |
| Stock-based compensation expense | 20 | 22 |
| Other, net | 8 | (1) |
| Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts receivable | (180) | (101) |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | (12) | (53) |
| &nbsp;&nbsp;&nbsp;Income taxes payable | 13 | 15 |
| &nbsp;&nbsp;&nbsp;Other assets and liabilities, net | (31) | 49 |
| **Net cash provided by operating activities** | 278 | 314 |
| **Cash flows from investing activities:** |  |  |
| Business acquisitions, net of cash acquired | (38) |  |
| Capital expenditures | (114) | (117) |
| Other investing activities, net |  | 2 |
| **Net cash used in investing activities** | (152) | (115) |
| **Cash flows from financing activities:** |  |  |
| Proceeds from borrowings |  | 215 |
| Repayments of debt | (1) | (600) |
| Exercise of stock options | 65 | 29 |
| Employee payroll tax withholdings on stock issued under stock-based compensation plans | (37) | (42) |
| Dividends paid | (88) | (84) |
| Distributions to noncontrolling interest partners | (7) | (18) |
| Other financing activities, net | (84) | (61) |
| **Net cash used in financing activities** | (152) | (561) |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | (1) | 1 |
| **Net change in cash and cash equivalents and restricted cash** | (27) | (361) |
| **Cash and cash equivalents and restricted cash, beginning of period** | 420 | 549 |
| **Cash and cash equivalents and restricted cash, end of period** | $393 | $188 |
| **Cash paid during the period for:** |  |  |
| Interest | $22 | $32 |
| Income taxes | $8 | $4 |

---

------

**Notes to Financial Tables**

1)The computation of basic and diluted earnings per common share is as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| | (in millions, except per share data) | (in millions, except per share data) |
| **Amounts attributable to Quest Diagnostics' common stockholders:** |  |  |
| Net income attributable to Quest Diagnostics | $252 | $220 |
| Less: earnings allocated to participating securities | 1 | 1 |
| Earnings available to Quest Diagnostics' common stockholders - basic and diluted | $251 | $219 |
| Weighted average common shares outstanding - basic | 110 | 111 |
| Effect of dilutive securities: |  |  |
| &nbsp;&nbsp;&nbsp;Stock options and performance share units | 2 | 2 |
| Weighted average common shares outstanding - diluted | 112 | 113 |
| **Earnings per share attributable to Quest Diagnostics' common stockholders:** |  |  |
| Basic | $2.27 | $1.97 |
| Diluted | $2.24 | $1.94 |

---

2)The following tables reconcile reported GAAP results to non-GAAP adjusted results:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** |
| | **(dollars in millions, except per share data)** | **(dollars in millions, except per share data)** | **(dollars in millions, except per share data)** | **(dollars in millions, except per share data)** | **(dollars in millions, except per share data)** | **(dollars in millions, except per share data)** |
| | **Operating income** | **Operating income as a percentage of net revenues** | **Income tax expense (e)** | **Equity in earnings of equity method investees, net of taxes** | **Net income attributable to Quest Diagnostics** | **Diluted EPS** |
| As reported | $399 | 13.8% | $(74) | $4 | $252 | $2.24 |
| Restructuring and integration charges (a) | 7 | 0.2 | (2) |  | 5 | 0.04 |
| Other charges (b) | 4 | 0.1 | (1) |  | 3 | 0.03 |
| Gains and losses on investments (c) |  |  | (2) | 7 | 5 | 0.05 |
| Amortization expense | 37 | 1.3 | (9) |  | 28 | 0.25 |
| ETB |  |  | (12) |  | (12) | (0.11) |
| As adjusted | $447 | 15.4% | $(100) | $11 | $281 | $2.50 |

---

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** |
| | **(dollars in millions, except per share data)** | **(dollars in millions, except per share data)** | **(dollars in millions, except per share data)** | **(dollars in millions, except per share data)** | **(dollars in millions, except per share data)** | **(dollars in millions, except per share data)** |
| | **Operating income** | **Operating income as a percentage of net revenues** | **Income tax expense (e)** | **Equity in earnings of equity method investees, net of taxes** | **Net income attributable to Quest Diagnostics** | **Diluted EPS** |
| As reported | $346 | 13.0% | $(59) | $18 | $220 | $1.94 |
| Restructuring and integration charges (a) | 19 | 0.7 | (5) |  | 14 | 0.13 |
| Other charges (b) | 2 | 0.1 |  |  | 2 | 0.02 |
| Other gains (d) |  |  | 2 | (8) | (6) | (0.06) |
| Amortization expense | 39 | 1.5 | (9) |  | 30 | 0.26 |
| ETB |  |  | (9) |  | (9) | (0.08) |
| As adjusted | $406 | 15.3% | $(80) | $10 | $251 | $2.21 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)For both the three months ended March 31, 2026 and 2025, the pre-tax impact represents costs primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business. The following table summarizes the pre-tax impact of restructuring and integration charges on our consolidated statements of operations:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| | (dollars in millions) | (dollars in millions) |
| Cost of services | $1 | $6 |
| Selling, general and administrative | 6 | 13 |
| &nbsp;&nbsp;&nbsp;Operating income | $7 | $19 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)For both the three months ended March 31, 2026 and 2025, the pre-tax impact primarily represents a loss associated with the change in the fair value of the contingent consideration accrual associated with previous acquisitions, recorded in other operating expense, net.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)For the three months ended March 31, 2026, the pre-tax impact represents losses associated with changes in the carrying value of our strategic investments, principally recorded in equity in earnings of equity method investees, net of taxes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)The three months ended March 31, 2025 includes pre-tax gains of $8 million, recorded in equity in earnings of equity method investees, net of taxes, principally consisting of a non-recurring gain related to a lease.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)For restructuring and integration charges, other gains/charges, gains and losses on investments, and amortization expense, income tax impacts, where recorded, were primarily calculated using combined statutory income tax rates of 25.5% for both 2026 and 2025. No income tax impact was recorded on losses associated with the change in the fair value of the contingent consideration accrual associated with previous acquisitions.

3)The outlook for adjusted diluted EPS represents management's estimates for the full year 2026 before the impact of special items. Further impacts to earnings related to special items may occur throughout 2026. Additionally, the amount of ETB is dependent upon employee stock option exercises and our stock price, which are difficult to predict. The following table reconciles our 2026 outlook for diluted EPS under GAAP to our outlook for adjusted diluted EPS:

------

---

| | | |
|:---|:---|:---|
| | **Low** | **High** |
| Diluted EPS | $9.58 | $9.78 |
| Restructuring and integration charges (a) | 0.10 | 0.10 |
| Amortization expense (b) | 0.99 | 0.99 |
| Other charges (c) | 0.10 | 0.10 |
| Gains and losses on investments (d) | 0.05 | 0.05 |
| ETB | (0.19) | (0.19) |
| Adjusted diluted EPS | $10.63 | $10.83 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Represents estimated pre-tax charges of $16 million primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business. Income tax benefits were primarily calculated using a combined statutory income tax rate of 25.5%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Represents estimated pre-tax amortization expenses of $149 million. Income tax benefits were primarily calculated using a combined statutory income tax rate of 25.5%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Principally represents estimated pre-tax net losses of $10 million associated with the increase in the fair value of the contingent consideration accrual associated with previous acquisitions. Such estimate is subject to the risks and uncertainties discussed in the "Forward Looking Statements" section above. No income tax benefits are recorded on the changes associated with the contingent consideration accrual.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Income tax impacts were calculated using a combined statutory income tax rate of 25.5%.

<br>